~~<i id='15FD53A880'><strike id='15FD53A880'><tt id='15FD53A880'><pre id='15FD53A880'></pre></tt></strike></i>~~

Home» leisure time» fashion

fashion

author：knowledge 2025-10-09 06:56:54 Page View：166

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare wants to send $9 billion to 340B hospitals
Next article： Novavax promises a turnaround & Lilly roils the obesity market

explore

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Adam's Take: Intra

MollyFerguson/STATIamoneweekawayfromthelaunchofmyweeklyemailnewsletter!It’scalledAdam’sBiotechScorec

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Isthereacureforallergies?HastheFDAbecometooflexible?Andwhichdrugsmakeyoumuscular?Wecoverallthatandmo